Group 1 - The core viewpoint of the news is that Anjisi's stock has experienced fluctuations, with a recent decline of 2.06% and a total market value of 5.167 billion yuan as of January 16 [1] - Anjisi's stock price has increased by 8.65% since the beginning of the year, with a 1.26% rise over the last five trading days and a 9.64% increase over the last 20 days, while it has decreased by 3.37% over the last 60 days [2] - The company, established on December 6, 2010, specializes in the research, production, and sales of minimally invasive diagnostic and therapeutic instruments, with its main revenue sources being GI category (62.74%), EMR/ESD category (23.26%), ERCP category (11.04%), instruments (2.21%), and others (0.74%) [2] Group 2 - As of January 10, 2025, Anjisi had 6,786 shareholders, an increase of 6.58% from the previous period, with an average of 6,124 circulating shares per person, a decrease of 6.17% [2] - For the period from January to September 2025, Anjisi achieved a revenue of 459 million yuan, representing a year-on-year growth of 7.51%, while the net profit attributable to the parent company was 177 million yuan, a decrease of 10.35% year-on-year [2] - Since its A-share listing, Anjisi has distributed a total of 239 million yuan in dividends [3]

杭州安杰思医学科技股份有限公司 2026 年第一次临时股东会会议资料 证券代码：688581 证券简称：安杰思 杭州安杰思医学科技股份有限公司 | | | 杭州安杰思医学科技股份有限公司 2026 年第一次临时股东会会议资料 杭州安杰思医学科技股份有限公司 2026 年第一次临时股东会会议须知 为维护广大投资者的合法权益，保障股东在本次股东会期间依法行使权利， 根据《公司法》、中国证监会《上市公司股东会规则》和公司《股东会议事规则》 等有关规定，特制定本会议须知： 2026 年第一次临时股东会 会议资料 2026 年 1 月 一、公司负责本次股东会的议程安排和会务工作,为确认出席会的股东或其 代理人或其他出席者的出席资格，会议工作人员将对出席会议者的身份进行必要 的核对工作，请被核对者给予配合。 二、出席会议的股东及股东代理人须在会议召开前半小时到会议现场办理签 到手续，并按规定出示证券账户卡、身份证明文件或营业执照/注册证书复印件 （加盖公章）、授权委托书等，上述登记材料均需提供复印件一份，个人登记材 料复印件须个人签字，法定代表人证明文件复印件须加盖公司公章，经验证后方 可出席会议。会议开始后,由会议主持 ...

Core Viewpoint - The company plans to hold its first extraordinary general meeting in 2026 to discuss two key proposals regarding its subsidiary, Hang'an Medical [1] Group 1: Capital Increase - The company intends to increase its investment in Hang'an Medical by 65 million yuan, with minority shareholders waiving their preemptive rights [1] - Following the capital increase, Hang'an Medical's registered capital will rise from 55 million yuan to 120 million yuan, and the company's ownership stake will increase from 90.91% to 95.83% [1] Group 2: Credit Guarantee - To support Hang'an Medical's operational and project investment needs, the company plans to provide a guarantee for a credit facility of up to 360 million yuan, with an authorization period of 12 months [1] - Hang'an Medical is currently in a growth phase and has obtained multiple medical device registration certificates [1]

Group 1 - The core point of the article is that Anjisi has reported the number of its shareholders as of January 10, 2026, which stands at 6,786 households [2]

Core Viewpoint - The company announced that its subsidiary, Hang An Medical Technology (Hangzhou) Co., Ltd., plans to apply for a comprehensive credit line of up to RMB 360 million to support its daily operations and high-end medical equipment project investments [1] Group 1: Financial Details - Hang An Medical intends to secure a credit line not exceeding RMB 360 million from banks and other financial institutions [1] - The company plans to provide a guarantee of up to RMB 360 million for the aforementioned credit line, which can be used cyclically within its validity period [1] - As of the announcement date, the company and its subsidiaries have a total external guarantee balance of RMB 0, with no overdue guarantees [1] Group 2: Corporate Governance - The guarantee matter has been approved by the company's third board of directors at its eighth meeting and is subject to shareholder meeting approval [1] - Hang An Medical is a subsidiary in which the company holds a 90.9091% stake and is currently in a growth development phase [1] - The company assesses the operational risks associated with Hang An Medical as manageable [1]

Group 1 - The core viewpoint of the article is that Anjisi (688581.SH) is making a strategic investment in Hang'an Medical to deepen its high-end diagnostic equipment industry layout, marking a key move in the company's long-term development plan in research and manufacturing [1] - The company plans to invest 65 million yuan of its own funds to increase its stake in Hang'an Medical, which is a minority shareholder of Hang'an Medical's employee equity incentive platform [1] - After the capital increase, Hang'an Medical's registered capital will change from 55 million yuan to 120 million yuan, and the company's ownership in Hang'an Medical will increase from 90.9091% to 95.8333%, maintaining its status as a controlling subsidiary [1]

中信证券股份有限公司 关于杭州安杰思医学科技股份有限公司 向控股子公司增资的核查意见 中信证券股份有限公司（以下简称"保荐人"）作为杭州安杰思医学科技股 份有限公司（以下简称"安杰思"或"公司"）首次公开发行股票并在科创板上 市的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板 股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范 运作》等文件的要求，对安杰思向控股子公司增资的事项进行了核查，具体情况 如下： 一、增资概述 （一）增资标的基本概况 1、本次交易概况 安杰思拟以自有资金 6,500 万元对其控股子公司杭安医学科技（杭州）有限 公司（以下简称"杭安医学"）进行增资，杭安医学的少数股东杭州鼎亮企业管 理合伙企业（有限合伙）（以下简称"杭州鼎亮"）系杭安医学的员工股权激励平 台，拟自愿放弃上述增资的优先认缴出资权。本次增资完成后，杭安医学注册资 本由 5,500 万元变更为 12,000 万元，安杰思持有杭安医学的股权比例由增资前的 90.9091%变更为 95.8333%，杭安医学仍为安杰思的控股子公司，不会导致安杰 思合并报表范围发生变更。 2、本次交易的交 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资标的名称：杭安医学科技（杭州）有限公司（以下简称"杭安医学"）， 为杭州安杰思医学科技股份有限公司（以下简称"安杰思"或"公司"）的控股 子公司。 本次投资概述：公司拟以自有资金 6,500 万元对杭安医学进行增资，杭 安医学的少数股东杭州鼎亮企业管理合伙企业（有限合伙）（以下简称"杭州鼎 亮"）拟放弃上述增资的优先认缴出资权。本次增资完成后，杭安医学注册资本 由 5,500 万元变更为 12,000 万元，公司持有杭安医学的股权比例由增资前的 90.9091%变更为 95.8333%，杭安医学仍为公司的控股子公司，不会导致公司合 并报表范围发生变更。 杭安医学系公司的控股子公司，杭安医学的少数股东杭州鼎亮为公司实 际控制人、董事长、总经理张承担任执行事务合伙人的股权激励平台，故公司本 次增资构成与关联方共同投资，但不构成《上市公司重大资产重组管理办法》规 定的重大资产重组。本次交易实施不存在重大法律障碍。 证券代码：688581 证券简称：安杰思 公告编号： ...

关于为控股子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：688581 证券简称：安杰思 公告编号：2026-002 杭州安杰思医学科技股份有限公司 担保对象及基本情况 | 被担保人名称 | 本次担保金额 | 实际为其提供的 担保余额（不含 | 是否在前期预 | 本次担保是否 | | --- | --- | --- | --- | --- | | | | 本次担保金额） | 计额度内 | 有反担保 | | 杭安医学科技（杭 州）有限公司 | 不超过人民币 36,000 万元 | 万元 | 不适用：前期不 存在预计额度 | 否 | | | | 0 | | | | | | | 情形 | | 累计担保情况 | 对外担保逾期的累计金额（万元） | 不适用 | | --- | --- | | 截至本公告日上市公司及其控股子公 | 0 | | 司对外担保总额（万元） | | | 对外担保总额占上市公司最近一期经 | 0 | | 审计净资产的比例（%） | | | 净资产 特别风险提示（如有请 ...

证券代码：688581 证券简称：安杰思 公告编号：2026-003 杭州安杰思医学科技股份有限公司 关于召开2026年第一次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2026年第一次临时股东会 召开日期时间：2026 年 1 月 26 日 15 点 30 分 召开地点：杭州市临平区兴中路 389 号三楼 302 会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2026 年 1 月 26 日 至2026 年 1 月 26 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过 股东会召开日期：2026年1月26日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 （二） 股东会召集人：董事会 （三） 投票方式：本次股东会所采用的表决 ...